Investment Rating - The report provides a positive outlook on the pharmaceutical and biotechnology sector, highlighting a weekly increase of 2.21%, outperforming the Wind All A index and the CSI 300 index [2][7]. Core Insights - The report emphasizes the impressive performance of domestic innovative drugs at the 2025 American Society of Clinical Oncology (ASCO) annual meeting, with over 70 oral presentations and more than 10 significant studies, indicating a growing participation of domestic innovative drugs [2][10]. - The report notes significant advancements in dual antibodies and ADC fields, with new mechanisms and targets emerging, suggesting a differentiated layout in early clinical stages [2][10]. - The report recommends focusing on early differentiated directions in anti-tumor drugs and long-term attention on biotech and traditional pharmaceutical companies deeply involved in dual antibodies and ADCs [2][10]. Summary by Sections Market Weekly Review - The pharmaceutical and biotechnology sector rose by 2.21% from May 26 to May 30, outperforming the Wind All A index (-0.02%) and the CSI 300 index (-1.08%) [7]. - The best-performing sub-sectors included other biological products (4.65%), chemical preparations (4.27%), and medical research outsourcing (4.0%), while offline pharmacies saw a decline of 2.69% [7][8]. - Notable individual stock performances included Shuyou Shen (60.4%), Huason Pharmaceutical (42%), and Changshan Pharmaceutical (35.9%) [10]. Industry News and Key Company Announcements - On May 30, Summit Therapeutics announced positive results from the global Phase III clinical trial of the dual antibody Ivorosi, achieving the primary endpoint of progression-free survival (PFS) [10][12]. - The report highlights the collaboration between Xinnuo Wei Pharmaceutical and Astellas for the development of a new generation antibody-drug conjugate, with an upfront payment of $130 million and potential milestone payments totaling up to $1.34 billion [12][13]. - The report also mentions various companies receiving approvals for innovative drugs and therapies, indicating a vibrant pipeline in the industry [14][15].

截至2025年5月30日收盘，维力医疗（603309）报收于12.07元，较上周的12.28元下跌1.71%。本周，维 力医疗5月28日盘中最高价报12.45元。5月29日盘中最低价报11.83元。维力医疗当前最新总市值35.35亿 元，在医疗器械板块市值排名90/126，在两市A股市值排名3758/5146。 本周关注点 维力医疗关于募集资金使用完毕并注销募集资金专户的公告 广州维力医疗器械股份有限公司发布公告，宣布2021年非公开发行股票募集资金已按规定全部使用完 毕，所有募集资金专户均已注销。公司非公开发行人民币普通股29632218股，发行价格每股13.48元， 募集资金总额为399442298.64元，净额为392814940.16元。募集资金到位情况由华兴会计师事务所审 验。 公司根据相关法律法规制定了《维力医疗募集资金管理制度》，开设了募集资金专项账户，并与开户银 行及保荐机构中信证券签订了监管协议，确保募集资金专款专用。募集资金专项账户分别用于营销中心 建设项目、一次性使用合金涂层抗感染导尿管生产建设项目、研发中心建设项目和血液净化体外循环管 路生产扩建项目，这些账户现已全部注销。 其中，研发 ...